Highlights MaaT Pharma

Equities

MAAT

FR0012634822

Market Closed - Euronext Paris Other stock markets 08:52:07 2024-04-30 am EDT			5-day change	1st Jan Change
9.3 ^EUR	-0.64%		+6.41%	+33.24%

Apr. 15	MaaT Pharma: positive data in graft-versus-host disease	CF
Apr. 15	MaaT Pharma Presents Positive 18-Month Data for MaaT013 Showing a Clear Overall Survival Advantage in aGvHD from the Early Access Program at the 2024 EBMT Event	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

MaaT Pharma: positive data in graft-versus-host disease	Apr. 15	CF
MaaT Pharma Presents Positive 18-Month Data for MaaT013 Showing a Clear Overall Survival Advantage in aGvHD from the Early Access Program at the 2024 EBMT Event	Apr. 15	CI
MaaT Pharma Presents Promising Preclinical Data at AACR for MaaT034 Aiming to Improve Patients? Responses to Immunotherapies	Apr. 08	CI
MaaT Pharma SA Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 28	CI
MaaT Pharma: Phase 2 trial recruitment completed	Mar. 05	CF
Maat Pharma Indicates Completion of Patient Recruitment for the Phase 2a Investigator-Sponsored Randomized Clinical Trial Evaluating Maat013 in Combination with Immune Checkpoint Inhibitors in Metastatic Melanoma	Mar. 05	CI
MaaT Pharma to Receive EUR7 Million Government Funding for Blood Cancer Therapy Study	Dec. 01	MT
MaaT Pharma SA Announces Its Ongoing Phase 2B Trial, Called Phoebus, Aimed At Evaluating MaaT033 to Improve Overall Survival for Patients Receiving allo-HSCT2	Nov. 30	CI
MaaT Pharma Announces First Patient Dosed in Phase 2b Randomized Clinical Trial Evaluating MaaT033 in Patients Receiving Allo-HSCT	Nov. 06	CI
MaaT Pharma’s Late-stage Study for MaaT013 Gets Data Safety Monitoring Board's Nod	23-10-26	MT
MaaT Pharma Announces Positive Outcome Following DSMB Review Reinforcing Confidence in Phase 3 On-Going Trial in Acute Graft-Versus-Host Disease with MaaT013	23-10-26	CI
MaaT Pharma SA Reports Earnings Results for the Half Year Ended June 30, 2023	23-09-26	CI
Correction: MaaT Pharma, Skyepharma Complete French Manufacturing Facility for Microbiome Ecosystem Therapies	23-09-12	MT
MaaT Pharma, Skyepharma Complete French Manufacturing Facility for Microbiome Ecosystem Therapies	23-09-12	MT
MaaT Pharma Announces Publication of Results in eClinicalMedicine Journal Highlighting Clinical Benefit of MaaT013 in AGvHD	23-07-26	CI
MaaT Pharma to Present Clinical Data for MaaT013 and MaT033 at 49th EBMT Annual Meeting	23-04-11	CI
MaaT Pharma SA Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-30	CI
Global markets live: Airbus, Manchester United, EA, Credit Suisse, Warner...	23-03-30
MaaT Pharma Receives Two Clinical Trial Application Authorizations to Evaluate MaaT033 in Two Therapeutic Indications in Europe	23-03-27	CI
MaaT Pharma Receives U.S. FDA Response Outlining Path Forward for Investigational New Drug Application for MaaT013 in Patients with Acute Graft-versus-Host Disease	23-02-03	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights MaaT Pharma

Equities

MAAT

FR0012634822

Highlights

Filters